Optio attends Huntington’s Disease Society of America 33rd annual convention – Los Angeles, June 2018

Optio further reinforces its expertise in neurodegenerative and rare diseases by attending  the 33rd annual HDSA convention held on June 7-9 in Los Angeles.  Optio has over 10 years of strategic pharmaceutical market planning and global pharmaceutical market development experience in the Huntington’s disease therapeutic arena. Optio has advanced the understanding of the HD market by providing actionable insights from a patient, caregiver, clinician and thought leader perspective through market research projects for a variety of pharmaceutical companies.